The ATXN3 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which ATXN3 has been disrupted to generate a loss-of-function model. This polyclonal format provides a heterogeneous pool of edited cells, avoiding clonal selection bias and enabling population-level functional analyses.
The parental A-549 cell line, derived from a lung adenocarcinoma of a 58-year-old Caucasian male, exhibits adherent epithelial morphology. A-549 is a widely utilized in vitro model for non-small cell lung cancer, employed to investigate mechanisms of tumorigenesis, metastasis, drug resistance, and signal transduction.
ATXN3 encodes a deubiquitinating enzyme that edits polyubiquitin chains, orchestrating protein degradation through the ubiquitin-proteasome system, aggresome formation, and autophagy. It interacts with VCP/p97 and HDAC6 to shuttle misfolded proteins to aggresomes and modulates NF-??B signaling via TRAF6 deubiquitination. ATXN3 is regulated by CHIP and CK2 and influences downstream effectors including parkin, p53, and PTEN, integrating protein quality control with transcriptional responses.
In the A-549 context, ATXN3 knockout enables dissection of its contributions to lung adenocarcinoma biology. A-549 cells harbor KRAS mutations and exhibit constitutive NF-??B activity, making them ideal for studying ATXN3-mediated NF-??B regulation and its impact on proliferation, apoptosis, and migration. This model also facilitates investigation of aggresome-autophagy pathways and chemosensitivity, highlighting ATXN3 as a nexus between protein homeostasis and oncogenic signaling.
Typical applications include cell viability, apoptosis, migration, and invasion assays to phenotype ATXN3-dependent behaviors. Western blotting and RT-qPCR validate knockout and assess targets such as parkin and p53. NF-??B reporter assays and ubiquitin chain analyses dissect signaling alterations, while immunofluorescence detects aggresome and autophagy markers like HDAC6 and LC3. Drug sensitivity screens for SCA3 or anticancer agents and co-immunoprecipitation of VCP/p97 and CHIP further exploit this model. For further information, please contact Ascent Research.
